Cencora, Inc. (NYSE:COR) Shares Sold by Left Brain Wealth Management LLC

Left Brain Wealth Management LLC lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 2.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 12,224 shares of the company’s stock after selling 291 shares during the period. Left Brain Wealth Management LLC’s holdings in Cencora were worth $2,746,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC grew its stake in shares of Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after buying an additional 46 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in Cencora during the 4th quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC boosted its holdings in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after acquiring an additional 69 shares during the period. Kentucky Trust Co purchased a new position in Cencora during the 4th quarter valued at about $33,000. Finally, WASHINGTON TRUST Co boosted its holdings in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock valued at $38,000 after acquiring an additional 46 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Cencora stock opened at $255.64 on Friday. The stock has a market cap of $49.57 billion, a P/E ratio of 36.36, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a fifty day simple moving average of $247.01 and a 200-day simple moving average of $238.93. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $263.70. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.86%. Cencora’s dividend payout ratio is presently 31.29%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on COR. Wells Fargo & Company raised their target price on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Mizuho began coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $277.90.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares of the company’s stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,648 shares of company stock worth $3,382,462. 10.80% of the stock is currently owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.